Seelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study

MT Newswires Live09-24

Seelos Therapeutics (SEEL) said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform clinical trial of potential treatments for post-traumatic stress disorder.

The company said it signed a material transfer agreement with the US Army Medical Materiel Development Activity to supply SLS-002, or intranasal racemic ketamine, for the study and dosing of the SLS-002 group is expected to start before the end of the year. Financial details were not disclosed.

Seelos said SLS-002 is the only ketamine-based therapy included in the study.

Shares of the company were up more than 85% in recent Tuesday premarket activity.

Price: 0.3521, Change: +0.16, Percent Change: +85.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2469449599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-24 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469449599","market":"us","top_or_hot":-1,"title":"Seelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study","media":"MT Newswires Live","content":"<html><body><p> Seelos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SEEL) said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform clinical trial of potential treatments for post-traumatic stress disorder.</p><p>The company said it signed a material transfer agreement with the US Army Medical Materiel Development Activity to supply SLS-002, or intranasal racemic ketamine, for the study and dosing of the SLS-002 group is expected to start before the end of the year. Financial details were not disclosed.</p><p>Seelos said SLS-002 is the only ketamine-based therapy included in the study.</p><p>Shares of the company were up more than 85% in recent Tuesday premarket activity.</p><p>Price: 0.3521, Change: +0.16, Percent Change: +85.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeelos Therapeutics Says Ketamine-Based Therapy Chosen for Government PTSD Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-24 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Seelos Therapeutics (SEEL) said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SEEL","symbol_name":"Seelos Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2469449599","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469449599","pubTimestamp":1727182816,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Seelos Therapeutics  said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform clinical trial of potential treatments for post-traumatic stress disorder.The company said it signed a material transfer agreement with the US Army Medical Materiel Development Activity to supply SLS-002, or intranasal racemic ketamine, for the study and dosing of the SLS-002 group is expected to start before the end of the year. Financial details were not disclosed.Seelos said SLS-002 is the only ketamine-based therapy included in the study.Shares of the company were up more than 85% in recent Tuesday premarket activity.Price: 0.3521, Change: +0.16, Percent Change: +85.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SEEL":"Seelos Therapeutics, Inc.","BK4139":"生物科技","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Seelos Therapeutics表示政府PTSD研究选择基于氯胺酮的疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SEEL":0.9},"content_text":"Seelos Therapeutics (SEEL) said Tuesday its investigational ketamine-based treatment, SLS-002, was selected for inclusion in the US Department of Defense's Military and Veterans Adaptive Platform clinical trial of potential treatments for post-traumatic stress disorder.The company said it signed a material transfer agreement with the US Army Medical Materiel Development Activity to supply SLS-002, or intranasal racemic ketamine, for the study and dosing of the SLS-002 group is expected to start before the end of the year. Financial details were not disclosed.Seelos said SLS-002 is the only ketamine-based therapy included in the study.Shares of the company were up more than 85% in recent Tuesday premarket activity.Price: 0.3521, Change: +0.16, Percent Change: +85.32","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2469449599"}